Naturecell네이처셀

Naturecell's trailing revenue is about ₩20.5B with a large operating loss, and the share price is down about 12% over the past year.

Naturecell is a small Korean stem cell company whose lead candidate, JointStem for knee osteoarthritis, is in US clinical trials, alongside culture media, cosmetics and health drinks. On trailing figures through H1 2026 it reports revenue of ₩20.5B, an operating loss of ₩3.7B and a net loss of ₩2.7B, with negative free cash flow of ₩22.5B. The share price closed at ₩21,800 on 26 October 2026, well below its 52-week high of ₩36,950.

What stands out

• Trailing operating margin is -17.9% and net margin is -13.2%, and 2025 revenue fell 35.9% from 2024, which had a one-off profitable year.
• Cash of ₩21.3B against borrowings of ₩17.0B; liabilities are 40.7% of equity.
• Price-to-book is 22.3 and price-to-sales is 68.5, while P/E is not meaningful because earnings are negative; dividend yield is 0%.
• Recent filings include a rights offering decision, a convertible bond issue, a share acquisition and a tangible asset acquisition decision, all in July to October 2026.
• Foreign ownership rose slightly to 7.4% from 7.1% over 60 days, while institutions net sold about ₩610M and retail net bought about ₩569M over the last 20 days.

What to watch

• Upcoming full-year 2026 results and whether losses narrow from the trailing level.
• Details of the rights offering and convertible bond, which could dilute existing shareholders; the data does not give terms.
• Progress of JointStem clinical trials, which the data does not describe in detail; no news headlines were available in the data.